Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure

Fisch, Jeffrey D; Keskintepe, Levent; Sher, Geoffrey

doi:10.1016/j.fertnstert.2007.03.004

Cited by 23 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients were stimulated with recombinant FSH using specific dosage algorithms as defined recently 18 and in most cases (49.0% of cycles) using an antagonist protocol. Other older patients received a flare-agonist regimen (33.5%) or specialised downregulation protocols (17.5%) 19 ( table 1 ). Ovulation was triggered with human chorionic gonadotropin (HCG).…”

Section: Methodsmentioning

confidence: 99%

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis

et al. 2017

View full text Add to dashboard Cite

BackgroundPatients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed in poor-prognosis women undergoing fresh IVF transfer cycles.MethodsData were retrospectively analysed from 400 IVF cycles, where 161 women received GH and 239 did not.ResultsClinical pregnancy, live birth rates and corresponding ORs and CIs were significantly greater with GH, despite patients being significantly older with lower ovarian reserve. Patient’s age, quality of transferred embryo and GH were the only significant independent predictors of clinical pregnancy (OR: 0.90, 5.00 and 2.49, p<0.002, respectively) and live birth chance (OR: 0.91, 3.90 and 4.75, p<0.014, respectively). GH increased clinical pregnancy chance by 3.42-fold (95% CI 1.82 to 6.44, p<0.0005) and live birth chance by 6.16-fold (95% CI 2.83 to 13.39, p<0.0005) after adjustment for maternal age, antral follicle count and transferred embryo quality.ConclusionThese data provided further evidence to indicate that GH may support more live births, particularly in younger women. It also appears that embryos generated under GH have a better implantation potential, but whether the biological mechanism is embryo-mediated or endometrium-mediated is unclear.

show abstract

Section: Methodsmentioning

confidence: 99%

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Ovarian stimulation, oocyte retrieval, and polar body biopsy After appropriate disclosure, each patient underwent controlled ovarian hyperstimulation as previously described (24). Human chorionic gonadotropin, 10,000 IU (Profasi; Organon Pharmaceuticals, Kenilworth, NJ) was used to trigger ovulation in all cases.…”

Section: Human Oocytesmentioning

confidence: 99%

High survival rate of metaphase II human oocytes after first polar body biopsy and vitrification: determining the effect of previtrification conditions

Keskintepe

Ağca

Sher

et al. 2009

Fertility and Sterility

Self Cite

View full text Add to dashboard Cite

“…Fanchin et al [18] suggested that luteal phase pretreatment with oral E2 or GnRH antagonist coordinates subsequent follicular growth during COS. This approach has been widely adopted in the treatment of low responders [19,20,21,22]. Estrogen pretreatment was also recently found useful in programming GnRH antagonist cycles [23].…”

Section: Discussionmentioning

confidence: 99%

Controlled Ovarian Stimulation Using a Long Gonadotropin-Releasing Hormone<b> </b>Antagonist Protocol: A Proof of Concept and Feasibility Study

Weissman

Ravhon²,

Steinfeld³

et al. 2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: To evaluate the feasibility of a long protocol of controlled ovarian stimulation prior to in vitro fertilization (IVF) and embryo transfer with a gonadotropin-releasing hormone (GnRH) antagonist used for pituitary and ovarian suppression. Methods: Thirty patients undergoing IVF/intracytoplasmic sperm injection were randomized into two groups. The control group (n = 16) received a standard flexible GnRH antagonist protocol. Ovarian stimulation consisted of 225 IU/day of recombinant follicle-stimulating hormone for 5 days, followed by 225 IU/day of human menopausal gonadotropin until human chorionic gonadotropin (hCG) administration. The study group (n = 14) received 0.25 mg of GnRH antagonist daily for 7 days, thereafter, upon confirmation of pituitary and ovarian suppression, ovarian stimulation was commenced with the same protocol as used in the control group. Hormone and follicle dynamics, as well as laboratory characteristics and cycle outcome, were compared for both groups. Results: Both groups were comparable in baseline characteristics. Pituitary and ovarian suppression were effectively achieved in 12/14 patients in the study group. The duration of ovarian stimulation and gonadotropin consumption were similar in both groups, as was also the number and size of follicles on hCG day. Conclusion: The results of our study confirm the feasibility of a long GnRH antagonist protocol. This regimen could become another option to optimize GnRH antagonist protocols, and should thus be further explored.

show abstract

Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure

Cited by 23 publications

References 40 publications

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis

High survival rate of metaphase II human oocytes after first polar body biopsy and vitrification: determining the effect of previtrification conditions

Controlled Ovarian Stimulation Using a Long Gonadotropin-Releasing Hormone<b> </b>Antagonist Protocol: A Proof of Concept and Feasibility Study

Contact Info

Product

Resources

About